Highdose Ara-C/Idarubicin induction and high dose Etoposide/Cytoxan intensification in AML.

被引：0
|
作者：
Kurian, S [1 ]
Qazilbash, MH [1 ]
Lynch, JP [1 ]
Beall, CL [1 ]
Weisenborn, R [1 ]
Bunner, P [1 ]
Hobbs, G [1 ]
Auber, M [1 ]
Ericson, SG [1 ]
机构：
[1] W Virginia Univ, Bone Marrow Transplant Program, Morgantown, WV USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4641
引用
收藏
页码：213B / 213B
页数：1
相关论文
共 50 条
  • [21] Feasibility study of temozolomide maintenance therapy in elderly patients with AML following induction therapy with high dose mitoxantrone and high dose ara-C
    Ponce, Doris
    Katragadda, Sreedhar
    Liu, Delong
    Rasul, Muhammad
    Ahmed, Nasir
    Ahmed, Tauseef
    Seiter, Karen
    BLOOD, 2007, 110 (11) : 164B - 164B
  • [22] Phase II study of gemtuzumab ozogamycin (GO) and cytarabine (ARA-C) in patients with high risk MDS and AML.
    Kang, P
    Seiter, K
    Liu, DL
    Arshad, M
    Qureshi, A
    Nelson, J
    Ahmed, T
    BLOOD, 2004, 104 (11) : 264B - 264B
  • [23] A combination of idarubicin, fludarabine, Ara-C and G-CSF (IFLAG) induction followed by high dose busulfan/cytoxan and peripheral blood stem cell rescue in patients with myelodysplastic syndrome in transformation and poor prognosis acute myelogenous leukemia (AML).
    Besa, EC
    Trottman, J
    Klease, C
    Brehm, P
    Rovito, M
    BLOOD, 1995, 86 (10) : 3148 - 3148
  • [24] HIGH-DOSE ARA-C AND ETOPOSIDE IN THE TREATMENT OF REFRACTORY OR RELAPSING ACUTE-LEUKEMIA
    FREUND, M
    LINK, H
    DIEDRICH, H
    WILKE, JJ
    SCHMOLL, HJ
    POLIWODA, H
    BLUT, 1987, 55 (04): : 215 - 215
  • [25] HIGH-DOSE ARA-C - A SUMMARY
    SEEBER, S
    ONKOLOGIE, 1985, 8 (01): : 57 - 58
  • [26] STANDARD INDUCTION AND LOW-DOSE ARA-C TREATMENT IN PATIENTS OVER 60 WITH AML OR MDS
    VANGEEL, BM
    HUIJGENS, PC
    OSSENKOPPELE, GJ
    WIJERMANS, PW
    LANGENHUIJSEN, MMAC
    NETHERLANDS JOURNAL OF MEDICINE, 1989, 35 (3-4): : 128 - 136
  • [27] Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant.: A feasable and effective therapeutic strategy for de novo AML patients
    Clavio, M
    Gatto, S
    Beltrami, G
    Quintino, S
    Canepa, L
    Pierri, I
    Galbusera, V
    Carrara, P
    Miglino, M
    Varaldo, R
    Ballerini, F
    Venturino, C
    Cerri, R
    Risso, M
    Balleari, E
    Carella, AM
    Sessarego, M
    Ghio, R
    Bacigalupo, A
    Gobbi, M
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2002, 21 (04) : 481 - 487
  • [28] RELATIONSHIP OF [H-3] ARA-C INCORPORATION AND RESPONSE TO THERAPY WITH HIGH-DOSE ARA-C IN AML PATIENTS - A LEUKEMIA INTERGROUP STUDY
    RAZA, A
    GEZER, S
    ANDERSON, J
    LYKINS, J
    BENNETT, J
    BROWMAN, G
    GOLDBERG, J
    LARSON, R
    VOGLER, R
    PREISLER, HD
    EXPERIMENTAL HEMATOLOGY, 1992, 20 (10) : 1194 - 1200
  • [29] Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review
    Fajardo-Orduna, Guadalupe Rosario
    Ledesma-Martinez, Edgar
    Aguiniga-Sanchez, Itzen
    Mora-Garcia, Maria de Lourdes
    Weiss-Steider, Benny
    Santiago-Osorio, Edelmiro
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (09)
  • [30] INTERMEDIATE HIGH-DOSE ARA-C (I-HIDAC) - TOXICITY AND REMISSION INDUCTION IN POOR-RISK AML
    MITROU, PS
    HOELZER, D
    GANSER, A
    BERGMANN, L
    BLUT, 1986, 53 (03): : 243 - 243
12345